Evidence map›Paper›PMID 40234247›Full record

ArticleBioinformatics (Oxford, England)2025

adverSCarial: assessing the vulnerability of single-cell RNA-sequencing classifiers to adversarial attacks.

Ghislain Fievet, Julien Broséus, David Meyre, Sébastien Hergalant

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ghislain FievetINSERM U1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), University of Lorraine, Nancy, 54500, France.
Julien BroséusINSERM U1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), University of Lorraine, Nancy, 54500, France.
David MeyreINSERM U1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), University of Lorraine, Nancy, 54500, France.
Sébastien HergalantINSERM U1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), University of Lorraine, Nancy, 54500, France.ORCID 0000-0001-8456-7992

Funding

Contrat de Plan Etat-Régions-Biologie Santé du site Lorrain
6 · The paper itself

Abstract

motivationSeveral machine learning (ML) algorithms dedicated to the detection of healthy and diseased cell types from single-cell RNA sequencing (scRNA-seq) data have been proposed for biomedical purposes. This raises concerns about their vulnerability to adversarial attacks, exploiting threats causing malicious alterations of the classifiers' output with defective and well-crafted input.

resultsWith adverSCarial, adversarial attacks of single-cell transcriptomic data can easily be simulated in a range of ways, from expanded but undetectable modifications to aggressive and targeted ones, enabling vulnerability assessment of scRNA-seq classifiers to variations of gene expression, whether technical, biological, or intentional. We exemplify the usefulness and performance with a panel of attack modes proposed in adverSCarial by assessing the robustness of five scRNA-seq classifiers, each belonging to a distinct class of ML algorithm, and explore the potential unlocked by exposing their inner workings and sensitivities on four different datasets. These analyses can guide the development of more reliable models, with improved interpretability, usable in biomedical research and future clinical applications. AVAILABILITY AND IMPLEMENTATION: adverSCarial is a freely available R package accessible from Bioconductor: https://bioconductor.org/packages/adverSCarial/ or https://doi.org/10.18129/B9.bioc.adverSCarial. A development version is available at https://github.com/GhislainFievet/adverSCarial.

Indexed as

Machine LearningSequence Analysis, RNASingle-Cell AnalysisAlgorithmsGene Expression ProfilingHumansTranscriptome

Identifiers

PMID40234247
PMCPMC12036967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.